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SATB2 Shows Different Profiles Between Appendiceal 
Adenocarcinomas Ex Goblet Cell Carcinoids and 
Appendiceal/Colorectal Conventional Adenocarcinomas: An 
Immunohistochemical Study With Comparison to CDX2
Chen Yanga, e, Li Sunb, e, Lingxin Zhanga, Lixin Zhoub, Dongfeng Niub, Wenfeng Caoc,  
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Abstract
Background: Special AT-rich sequence-binding protein 2 (SATB2) 
is a novel marker for colorectal adenocarcinomas but little is known 
about its expression in appendiceal adenocarcinomas. We aim to in-
vestigate SATB2 in these tumors and colorectal adenocarcinomas 
with comparison to CDX2.
Methods: Immunohistochemical stains for SATB2 and CDX2 were 
performed in 49 appendiceal adenocarcinomas (23 conventional, 26 
adenocarcinoma ex goblet cell carcinoids (AdexGCCs)) and 57 colo-
rectal adenocarcinomas. Their expression was correlated with tumor 
differentiation and growth patterns.
Results: SATB2 staining was positive in 26/26 (100%) appendiceal 
AdexGCCs and 15/23 (65%) appendiceal conventional adenocarci-
nomas (P = 0.001). Their mean percentage of SATB2-positive cells 
was 93% and 34%, respectively (P < 0.0001). CDX2 staining was 
seen in 26/26 (100%) AdexGCCs and 22/23 (96%) appendiceal con-
ventional adenocarcinomas (P = 0.4694). SATB2 and CDX2 showed 
similar staining in AdexGCCs but CDX2 labeled more tumor cells 
than SATB2 in conventional adenocarcinomas (mean 84% vs. 34%, P 
< 0.0001). SATB2 and CDX2 staining was seen in 82% (47/57) and 
96% (55/57) colorectal adenocarcinomas, respectively (P = 0.01). The 
mean percentage of cells positive for SATB2 and CDX2 was 48% and 
91%, respectively (P < 0.00001). Decreased SATB2 immunoreactiv-
ity was associated with non-glandular differentiation particularly sig-
net ring cells in colorectal (P = 0.001) and appendiceal conventional 
adenocarcinomas (P = 0.04) but not in appendiceal AdexGCCs.
Conclusions: SATB2 is a highly sensitive marker for appendiceal 
AdexGCCs with similar sensitivity as CDX2. In colorectal and ap-
pendiceal conventional adenocarcinomas, SATB2 is not as sensitive as 
CDX2 and its immunoreactivity is dependent on tumor differentiation.
Keywords: SATB2; CDX2; Adenocarcinoma ex goblet cell carci-
noid; Colorectal adenocarcinoma; Appendiceal adenocarcinoma
Introduction
Special AT-rich sequence-binding protein 2 (SATB2) is a 
DNA-binding protein involved in transcriptional regulation 
and chromatin remodeling [1-4]. Studies have shown that 
SATB2 is a diagnostic marker for osteoblastic differentiation 
in bone and soft tissue tumors [5] and it is also highly expressed 
in hindgut well differentiated neuroendocrine tumor [6]. Mag-
nusson et al first showed that SATB2 is a sensitive marker for 
colorectal adenocarcinoma (sensitivity 85.8% for primary and 
81.3% for metastasis) with high specificity [7], further con-
firmed by several other studies [8-12]. Although these studies 
indicate that SATB2 is a more specific marker than CDX2 for 
colorectal adenocarcinomas, 15-20% tumors do not show stain 
for SATB2 and little is known about the pathologic features 
associated with negative SATB2 staining [13].
Compared to colorectal adenocarcinomas, information on 
SATB2 expression in appendiceal adenocarcinomas is very 
limited [10, 14-15]. Most of the appendiceal tumors investi-
gated were low grade mucinous neoplasms and only two pri-
mary appendiceal adenocarcinomas were assessed [10, 14-15]. 
Appendiceal adenocarcinomas consist of conventional adeno-
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carcinoma (similar to colorectal adenocarcinoma) and adeno-
carcinoma ex goblet cell carcinoid (AdexGCC) [16]. The for-
mer has adenoma as its precursor whereas the latter arises from 
goblet cell carcinoid (GCC). GCC is also classified as mixed 
adenoneuroendocrine carcinoma in 2010 WHO classification 
[16]; however, studies have shown that it is a particular type of 
adenocarcinoma [17, 18-22]. Tang et al [17] classified GCCs 
as typical GCCs (type A) and those with invasive adenocarci-
nomas (type B, with signet ring cell type carcinoma, and type 
C, with poorly differentiated adenocarcinoma type), though 
this classification may be somewhat less ideal [18, 21]. In our 
recent study, positive SATB2 staining was observed in all 19 
(100%) metastatic AdexGCCs, indicating SATB2 is a highly 
sensitive marker for metastatic AdexGCCs [23]. However, the 
immunohistochemical status of SATB2 in primary appendiceal 
AdexGCCs and conventional adenocarcinomas is unknown.
To address these questions, we investigated SATB2 im-
munohistochemical expression in a large series of 57 colorectal 
adenocarcinomas and 49 appendiceal adenocarcinomas (23 con-
ventional, 26 AdexGCCs). We correlated SATB2 immunoreac-
tivity with tumor differentiation and growth patterns in these 
tumors. We also compared SATB2 to CDX2 for their sensitivity.
Materials and Methods
Materials
This study was approved by the Institutional Review Board. 
The surgical pathology archive of Washington University was 
searched for colorectal/appendiceal adenocarcinomas with or 
without signet ring cells, pure signet ring cell carcinomas and 
appendiceal AdexGCCs. Fifty-seven in-house colorectal ad-
enocarcinomas (2011 to 2015) and 27 appendiceal adenocarci-
nomas (1990 to 2017) were collected. Hematoxylin and eosin 
slides were re-reviewed to confirm the diagnosis. Additional 
appendiceal adenocarcinomas were retrieved from Peking 
University Cancer Hospital (Beijing, China) (N = 11, 2011 to 
2014), Tianjin Cancer Hospital (Tianjin, China) (N = 9, 2011 
to 2016) and University of Florida (N = 2, 2017).
These 57 colorectal carcinomas were well differentiated 
(WD) in 11, moderately differentiated (MD) in 19 and poorly 
differentiated (PD) in 27. Among them, nine were pure (100%) 
glandular WD adenocarcinomas, 10 pure signet ring cell carci-
nomas (100% signet ring cells), and 38 adenocarcinomas with 
variable percentage of glandular, non-glandular non-signet ring 
cells and/or signet ring cells. Among 23 conventional type ap-
pendiceal adenocarcinomas (seven WD, eight MD, eight PD), 
four showed pure glandular growth, one was pure signet ring 
cell carcinoma, and 18 had mixed components (12 with mixed 
glandular and non-glandular non-signet ring cell components, 
one with mixed signet ring cell and non-glandular non-signet 
ring cell component, five with all three components). The ap-
pendiceal AdexGCCs typically show multiple growth patterns 
including typical cryptal pattern, poorly cohesive goblet/sig-
net ring cells and non-mucinous cells, microglandular/tubular 
glands and solid growth etc as described previously [16-17, 
20-21]. All 26 appendiceal AdexGCCs have at least focal 
background residual GCC.
Immunohistochemical staining
One to two representative formalin fixed paraffin tissue blocks 
containing tumor from each case were retrieved to generate 
4 µm thick unstained slides for immunohistochemical stain-
ing for SATB2 (dilution 1:100, clone EPNCIR 130A, Abcam, 
Cambridge, MA) and CDX2 (prediluted, clone EPR2764Y, 
Cell Marque, Rocklin, CA) on a Ventana Benchmark automated 
immunostainer (Ventana Medical Systems, Inc., Tucson, AZ) 
according to standard protocols with appropriate positive and 
negative controls. Chromogranin (prediluted, clone LK2H10, 
Ventana, Tucson, AZ) and synaptophysin (predilute, polyclonal, 
Cell Marque, Rocklin, CA) were also performed for AdexGCCs 
using a Ventana Benchmark automated immunostainer.
Only nuclear staining was considered positive for SATB2 
and CDX2. The staining was reviewed in a consensus manner 
(CY, LZ, DC) with a multiheaded microscope. The results were 
scored in a semi-quantitative pattern as 0 (< 1% cells), 1+ (1-
25%), 2+ (26-50%), 3+ (51-75%), 4+ (76-100%). The percent-
age of positive cells was visually estimated with 5% increment.
Statistical analysis
The Fisher exact test was used to compare percentage of cases 
with positive staining and the staining patterns. The paired and 
non-paired t-tests were used to compare the mean percentage 
of tumor cells stained with SATB2 and CDX2. P-value less 
than 0.05 was considered statistically significant.
Results
SATB2 expression in appendiceal adenocarcinomas ex 
goblet cell carcinoids (N = 26)
All 26 (100%) AdexGCCs showed positive SATB2 staining 
including 2+ in one (4%) (50% cells), 3+ in one (4%) (60% 
cells), and 4+ in 24 (92%). There is no SATB2 staining differ-
ence between AdexGCCs and background residual GCCs (Fig. 
1, 2). The mean percentage of SATB2-positive tumor cells in 
AdexGCCs was 93% (median 95%, range 50-100%). SATB2 
stained at least 90% tumor cells in 24/26 (92%) AdexGC-
Cs. Different growth patterns in AdexGCCs showed similar 
SATB2 staining (Fig. 2).
SATB2 expression in appendiceal conventional type adeno-
carcinomas (N = 23)
Positive SATB2 staining was seen in 15/23 (65%) appendiceal 
conventional adenocarcinomas, including in 6/7 (86%) WD, 4/8 
(50%) MD, and 5/8 (63%) PD (Table 1, Fig. 3). The mean per-
centage of SATB2-positive tumor cells was 52% for WD, 25% 
for MD, and 27% for PD adenocarcinomas, respectively (P > 
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0.05 between any two). Among the seven cases with a signet 
ring cell component, only three (43%) were positive for SATB2 
staining (mean positive cells: 11%; median 0, range 0-45%).
At the individual component/growth pattern level, the 
mean percentage of SATB2-positive tumor cells was 35% (me-
dian 10%, range 0-95%) in the 19 glandular components, 18% 
(median 3%, range 0-95%) in the 18 non-glandular non- signet 
ring cell components, and 7% (median 0%, range 0-30%) in 
the seven signet ring cell components (P = 0.02 for glandular 
vs. non-glandular, P = 0.06 for glandular vs. non-signet non-
glandular, P = 0.03 for glandular vs. signet ring cell).
SATB2 expression in colorectal adenocarcinomas (N = 57)
Positive SATB2 staining was seen in 47/57 (82%) colorec-
tal adenocarcinomas, including in 11/11 (100%) WD, 15/19 
(79%) MD, and 21/27 (78%) PD adenocarcinomas (semi-
quantitative staining pattern/0 to 4+: P = 0.009 for WD vs. MD 
vs. PD, P = 0.1218 for WD vs. MD, P = 0.001 for WD vs. PD, 
P = 0.073 for MD vs. PD, P = 0.007 for WD vs. MD + PD, P = 
0.002 for low grade vs. high grade) (Table 2, Fig. 4). The mean 
percentage of SATB2-positive cells was 84% for WD, 53% 
for MD, and 29% for PD adenocarcinomas, respectively (P < 
0.01 between any two). Among the 37 adenocarcinomas with a 
signet ring cell component, positive SATB2 staining was seen 
in 29 (78%) cases, including 11/13 (85%) cases with 1-50% 
signet ring cells, 12/14 (86%) cases with 50-95% signet ring 
cells, and 6/10 (60%; 2+ in four, 3+ in one, 4+ in one) pure 
signet ring cell carcinomas.
At the tumor component/growth pattern level, the mean 
percentage of SATB2-positive tumor in the 37 signet ring cell 
components was 24% (median 10%, range 0-95%), signifi-
cantly lower than 63% (median 80%, range 0-100%) in the 36 
glandular components and 49% (median 50%, range 0-95%) 
in the 29 non-glandular non- signet ring cell components (P = 
0.01). The glandular components had a higher percentage of 
SATB2-positive tumor cells than the non-glandular non-signet 
ring cell components, but their difference did not reach sta-
tistical significance (63% vs. 49%, P = 0.09). The glandular 
component in those with a pure glandular growth pattern (N = 
9) showed more SATB2 staining than that in those also with 
other growth patterns (N = 27) (83% vs. 56%, P = 0.06). The 
signet ring cell component showed similar SATB2 staining be-
tween those with mixed signet ring cells and other component 
(s) and those pure signet ring cell carcinomas (23% vs. 29%, 
P > 0.05).
Comparison of SATB2 staining between appendiceal ad-
enocarcinomas ex goblet cell carcinomas and appendiceal/
colorectal conventional adenocarcinomas
Appendiceal AdexGCCs (N = 26) showed significantly more 
SATB2 staining than conventional adenocarcinomas (N = 23) 
(percentage of cases positive for SATB2: 100% vs. 65%, P = 
0.001; P = 5.0 E-06 for semi-quantitative staining pattern (0 
to 4+); mean positive tumor cells 93% vs. 34%, P< 0.0001) 
(Table 3).
Appendiceal AdexGCCs also showed significantly more 
SATB2 staining than colorectal adenocarcinomas (percentage 
of cases positive for SATB2: 100% vs. 82%, P = 0.03; P = 0.004 
for semi-quantitative staining pattern (0 to 4+); P <0.0001 for 
mean positive tumor cells, 93% vs. 48%) (Table 3).
Figure 1. Expression of SATB2 in appendiceal goblet cell carcinoids. Goblet cell carcinoid is morphologically characterized by 
well-defined goblet cells in clusters or cohesive linear fashion infiltrating appendiceal wall and peri-appendiceal soft tissue (A, D). 
The tumor cells often show focal chromogranin (B) and synaptophysin (C) staining but diffuse staining for CDX2 (E) and SATB2 
(F).
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Comparison of SATB2 to CDX2 in appendiceal adenocar-
cinomas ex goblet cell carcinoids, appendiceal convention-
al adenocarcinomas and colorectal adenocarcinomas
All 26 (100%) appendiceal AdxeGCCs showed strong 4+ 
CDX2 staining (mean 98% positive cells, range 95-100%). 
There is no significant difference between SATB2 and CDX2 
in the semi-quantitative staining pattern (P = 0.3534). Both 
SATB2 and CDX2 showed 100% sensitivity for AdexGCCs (P 
= 1.0), however, CDX2 stained more tumor cells than SATB2 
(mean 98% vs. 93%, P = 0.02) (Table 3).
Positive CDX2 staining was seen in 22/23 (96%) appen-
diceal conventional adenocarcinomas but only 15 of 23 (65%) 
were positive for SATB2 (P = 0.01, Tables 1, 3). CDX2 showed 
similar staining among different degree of differentiation (Ta-
ble 2) and among different histologic patterns (mean positive 
cells: 86% for glandular component, 82% for signet ring cell 
component, 72% for non-glandular non-signet ring cell com-
ponent, P > 0.05). The number of mean SATB2-positive tu-
mor cells in these tumors was significantly lower than that for 
CDX2 (34% vs. 84%, P = 1.2E-05) (Table 3).
Among the 57 colorectal adenocarcinomas, 56 (98%) 
showed positive CDX2 staining, significantly higher than that 
Figure 2. Expression of SATB2 in appendiceal adenocarcinoma ex goblet cell carcinoid. The signet ring cell type may show des-
moplastic stroma and extracellular mucin pools (A1, A2) and irregular large nests and sheet (B1, B2). In the poorly differentiated 
adenocarcinoma type, the invasive adenocarcinoma may manifest as tubular glands (C1, C2) or individual to clusters to small 
nested undifferentiated cells with focal small glandular lumen (D1, D2). The invasive adenocarcinoma cells show diffuse SATB2 
staining (A3, B3, C3, D3).
Articles © The authors   |   Journal compilation ©  Gastroenterol Res and Elmer Press Inc™   |   www.gastrores.org 225
Yang et al  Gastroenterol Res. 2018;11(3):221-230
for SATB2 (47/57 or 82%) (P = 0.004) (Tables 2, 3). SATB2 
and CDX2 showed similar semi-quantitative staining pattern 
in 11 WD tumors (P = 0.5901) but CDX2 demonstrated signifi-
cantly more semi-quantitative staining than SATB2 in 19 MD 
and 27 PD tumors (P < 0.05, Table 2). The mean percentage 
of positive tumor cells for SATB2 and CDX2 was 84% and 
95% for WD adenocarcinomas (P = 0.04), 53% and 90% for 
MD (P = 0.006), 29% and 90% for PD adenocarcinomas (P 
< 0.00001), respectively. Different histologic patterns showed 
similar CDX2 staining (mean positive tumor cells: 91% in the 
glandular component, 95% in the signet cell component, 82% 
in the non-glandular non-signet ring cell component, P > 0.05 
between any two).
Discussion
In this study, we investigated SATB2 immunoreactivity in 26 
appendiceal AdexGCCs and 80 conventional appendiceal/
colorectal adenocarcinomas. Consistently high expression of 
SATB2 was seen in all histologic patterns including signet ring 
cells in all 26 (100%) AdexGCCs. However, only 65% (15/23) 
conventional appendiceal and 82% (47/57) colorectal adeno-
carcinomas showed SATB2 immunoreactivity.
Our findings indicate SATB2 is a highly sensitive diagnos-
tic marker for primary appendiceal AdexGCCs. We previously 
showed similar SATB2 sensitivity for metastatic appendiceal 
AdexGCCs (19/19 or 100%) [23]. The percentage of tumor 
cells with SATB2 immunoreactivity is high in both primary 
and metastatic AdexGCCs (average 93% in primary, 97% in 
metastasis) [23]. Prior to our study, there has been only one 
study on SATB2 in six high grade appendiceal adenocarcino-
mas (two primary cases, four metastatic cases) [10]. All these 
six tumors were positive for SATB2 but the authors did not 
specify the subtypes and the extent of positivity [10]. Two oth-
er studies showed positive SATB2 staining in 63/72 appendi-
ceal mucinous neoplasms (extent of positivity unknown) but it 
is unknown how many of these mucinous tumors are mucinous 
adenocarcinomas [14-15].
GCCs (with/without associated adenocarcinomas) often 
present with advanced stages and involve adjacent right co-
lon and ileum [16-17, 20-21]. In two large series, 78 of 110 
(71%) appendiceal GCCs presented with T4 disease [17, 20]. 
Reid et al showed that 58% (33/57) female patients had dis-
seminated gynecologic tract disease (mainly in the ovary) 
[21]. Due to the diffuse involvement of appendix and adja-
cent colon and abdominopelvic cavity, it is often difficult to 
determine whether a poorly differentiated adenocarcinoma 
with signet ring cells involving these organs is an appendiceal 
AdexGCC or a conventional appendiceal/colorectal adeno-
carcinoma with signet ring cells. Although these two types of 
adenocarcinomas are surgically managed similarly, there is 
some prognostic difference [17, 20]. Given their overlapping 
morphologic features, pathologists often rely on immunohis-
tochemical markers to facilitate the differential diagnosis. 
However, appendiceal AdexGCC and appendiceal/colorectal 
conventional PD adenocarcinoma show similar CDX2 and 
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(in 60% AdexGCCs, in 35-40% of PD and mucinous colo-
rectal adenocarcinomas, and 17% colorectal signet ring cell 
carcinomas) [24-28]. Although GCC is considered a mixed 
adenoneuroendocrine carcinoma, chromogranin and synap-
tophysin are often under-expressed, especially those with 
AdexGCCs. Hristov et al showed chromogranin and synap-
tophysin staining in 38% and 40% appendiceal GCCs with 
AdexGCCs, respectively [19]. Although there is no data on 
chromogranin and synaptophysin in primary colorectal ade-
nocarcinomas with signet ring cells, we recently showed that 
metastatic colorectal PD carcinomas with signet ring cells in 
the ovary showed positive chromogranin and synaptophysin 
in 31% and 62% cases, respectively [23]. Therefore these 
common markers including CDX2, CK7, CK20, chromogra-
nin and synaptophysin lack adequate sensitivity and specific-
ity to distinguish appendiceal AdexGCCs from conventional 
appendiceal/colorectal PD carcinomas with signet ring cells. 
Our current study indicates that SATB2 may have some di-
agnostic utility in some cases to distinguish appendiceal 
AdexGCCs from colorectal/appendiceal conventional adeno-
carcinomas with signet ring cells. Given the 100% sensitivity 
of SATB2 for appendiceal AdexGCCs, a poorly differenti-
ated carcinoma with signet ring cells involving appendix and 
adjacent colon showing negative SATB2 staining is unlikely 
to be an appendiceal AdexGCCs (negative predictive value 
100%). In our study, 22% colorectal and 57% appendiceal 
conventional adenocarcinomas with a signet ring cell com-
ponent were negative for SATB2 staining.
Distinguishing appendiceal AdexGCCs from conventional 
PD appendiceal/colorectal adenocarcinomas with signet ring 
cell not only has prognostic significance but also may affect 
the patients’ follow-up schedule and non-surgical treatment 
options. Appendiceal AdexGCCs only seldom show liver (4%) 
and lung (1%) metastasis despite their widespread growth 
in the abdominopelvic cavity [21]. Although this pattern is 
similar to appendiceal mucinous adenocarcinomas, it differs 
from PD colorectal adenocarcinomas with signet ring cells. 
Conventional colorectal adenocarcinomas eventually develop 
liver and lung metastasis in 50% and 10-20% cases, respec-
tively [29-30]. In addition, given the tendency of appendiceal 
AdexGCCs to recur in the peritoneal and pelvic space, these 
patients may benefit from additional intraoperative hyperther-
Figure 3. Expression of SATB2 and CDX2 in appendiceal conventional adenocarcinomas. The neoplastic glands typically show 
more SATB2 staining than non-glandular components such as individual tumor cells (A1: H&E, A2: SATB2). In some tumors, 
both glandular and non-glandular components may lose SATB2 expression (B1: moderately differentiated adenocarcinoma; B2: 
SATB2, top shows normal glands with strong SATB2 staining). Signet ring cells (C1) are also associated with decreased SATB2 
staining (C2). In contrast, CDX2 typically shows diffuse strong staining (A3 and C3) with occasional focal weak staining (B3).
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mic chemotherapy as used for disseminated appendiceal muci-
nous adenocarcinomas [31].
In this study, we also compared SATB2 to CDX2 for 
their sensitivity. We found that SATB2 was not as sensitive 
as CDX2 for conventional appendiceal and colorectal adeno-
carcinomas (Tables 1-3). The reported average sensitivity 
of SATB2 and CDX2 for colorectal adenocarcinomas was 
84.4% (60% to 97%) (N = 2028) and 97% (95% to 100%) 
(N = 508), respectively (P < 0.0001, Fisher exact test) [5-10]. 
Our results were in keeping with those from these prior stud-
ies [5-10]. However, our study differed from prior studies 
in that we correlated SATB2 immunoreactivity with tumor 
differentiation/growth pattern and delineated the histologic 
patterns associated with decreased SATB2 immunoreactivity. 
Previously Magnusson et al briefly mentioned that PD colo-
rectal adenocarcinomas showed an apparently less amount 
of staining than WD ones but they did not elaborate further 
[7]. We found SATB2 immunoreactivity in appendiceal/colo-
rectal conventional adenocarcinomas was associated with 
tumor differentiation, and presence of non-glandular differ-
entiation, particularly signet ring cells, is associated with de-
creased immunoreactivity. This feature of SATB2 has diag-
nostic implications. Negative SATB2 staining in a metastatic 
moderately to poorly differentiated adenocarcinoma does not 
exclude a colorectal origin as 21% such primary tumors have 
negative SATB2 staining. In addition, colorectal adenocarci-
nomas may lose SATB2 immunoreactivity during metastases 
(12% tumors in one prior study) [7]. Therefore using only 
SATB2 to confirm or exclude metastatic colonic adenocar-
cinoma will miss a significant percentage of cases (20%). In 
contrast, CDX2 demonstrates consistently high expression 
in colorectal adenocarcinomas of various differentiations/
growth patterns and their metastasis [7-13]. However, CDX2 
is less specific than SATB2 for colorectal adenocarcinoma 
[8-12, 32]. For example, 29% esophageal and 47% gastric 
adenocarcinomas are also positive for CDX2 [32] but they 
are only rarely positive for SATB2 [8]. Gastroesophageal ad-
enocarcinoma is often in the differential diagnosis for meta-
static colorectal adenocarcinoma. Therefore, when metastatic 
colorectal adenocarcinoma is in the differential diagnosis, 
both SATB2 and CDX2 should be included to increase the 
sensitivity and specificity.
Although AdexGCCs and conventional colorectal/ap-
pendiceal adenocarcinomas show morphologic overlapping, 
they have different genetic profiles. Studies have shown that 
frequently mutated genes in the colorectal adenocarcinomas 
including TP53, KRAS and APC were not or rarely mutated 
in AdexGCCs [33-34]. In contrast, AdexGCCs harbored mu-
tations in Wnt-signaling-associated genes including USP9X, 
NOTCH1, CTNNA1, CTNNB1 and TRRAP [34]. Appendiceal 
conventional and colorectal adenocarcinomas showed similar 
genetic mutations [33]. Different SATB2 immunohistochemi-
cal profiles between appendiceal AdexGCCs and appendi-
ceal/colorectal conventional adenocarcinomas add additional 
evidence that AdexGCCs are distinct tumors. AdexGCC and 
GCC are thought to arise from pluripotent intestinal epithelial 
crypt base stem cells (crypt cell carcinoma) [22, 26].
One limitation in our study is that the number of appendi-
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tumors are relatively uncommon [16].
Conclusions
In summary, SATB2 shows different immunohistochemical 
profiles between AdexGCCs and colorectal/appendiceal con-
ventional adenocarcinomas. SATB2 demonstrates consistently 
high expression in AdexGCCs but its immunoreactivity in 
colorectal/appendiceal conventional adenocarcinomas is asso-
ciated with tumor growth pattern and differentiation. SATB2 
and CDX2 show similar sensitivity for AdexGCCs but SATB2 
is not as sensitive as CDX2 for colorectal/appendiceal conven-
tional adenocarcinomas. Our study is the first one to investi-
Figure 4. Expression of SATB2 and CDX2 in colorectal adenocarcinomas. In colorectal adenocarcinomas, the neoplastic glands 
(A1 top) typically show diffuse strong SATB2 staining (A2) but signet ring cells, either admixed with glands (A1 bottom) or pure 
(B1) are associated with absent (A2 bottom) or decreased/weak (B2) SATB2 immunoreactivity. The presence of colloid carcino-
ma component (C1 bottom) is often associated with decreased or absent SATB2 staining (C2 botttom). Non-glandular non-signet 
ring cell component such as single cells, clusters and nests (C1, D1) are also associated with decreased (C2 middle) or absent 
(D2) SATB2 immunoreactivity. In D1, the neoplastic glands next to the discohesive tumor cells are also negative for SATB2 stain-
ing (D2). The background benign colonic glands show strong diffuse SATB2 staining (B2 to D2). In contrast, CDX2 demonstrates 
consistently diffuse staining across different growth patterns, mostly strong (A3 to C3) with occasional weak (D3) staining.
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gate SATB2 in primary appendiceal AdexGCCs and delineate 
the histologic patterns associated with deceased SATB2 im-
munoreactivity in colorectal/appendiceal conventional adeno-
carcinomas.
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